AU Patent

AU2021224989A1 — Methods of treating idiopathic hypersomnia

Assigned to Jazz Pharmaceuticals Ireland Ltd · Expires 2022-10-13 · 4y expired

What this patent protects

The present disclosure relates to the treatment of idiopathic hypersomnia with a mixture of salts of oxybate (mixed salt oxybate).

USPTO Abstract

The present disclosure relates to the treatment of idiopathic hypersomnia with a mixture of salts of oxybate (mixed salt oxybate).

Drugs covered by this patent

Patent Metadata

Patent number: AU2021224989A1
Jurisdiction: AU
Classification: —
Expires: 2022-10-13
Drug substance claim: No
Drug product claim: No
Assignee: Jazz Pharmaceuticals Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.